Cargando…
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients
INTRODUCTION: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with no validated specific and sensitive biomarker, and no standard approved treatment. In this observational study with no intervention, participants used a Fitbit activity tracker. The aims were to explore natur...
Autores principales: | Rekeland, Ingrid G., Sørland, Kari, Bruland, Ove, Risa, Kristin, Alme, Kine, Dahl, Olav, Tronstad, Karl J., Mella, Olav, Fluge, Øystein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484698/ https://www.ncbi.nlm.nih.gov/pubmed/36121803 http://dx.doi.org/10.1371/journal.pone.0274472 |
Ejemplares similares
-
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
por: Fluge, Øystein, et al.
Publicado: (2015) -
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
por: Rekeland, Ingrid G., et al.
Publicado: (2020) -
A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome
por: Hoel, Fredrik, et al.
Publicado: (2021) -
Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome–Results From Open-Label Cyclophosphamide Intervention Study
por: Sørland, Kari, et al.
Publicado: (2021) -
Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome
por: Lunde, Sigrid, et al.
Publicado: (2016)